Treatment with glucose lowering pharmacotherapy has an inherent risk for iatrogenic hypoglycemia, especially in older T2DM patients with a long diabetes duration treated with insulin or sulfonylurea [106]. This evidence concerns the gene INS and type 2 diabetes mellitus.